AOM tirzepatide prescriptions rates, which had been rising by an average of +0.06 percentage points per month (Jan 2024–Jun 2025), grew only +0.03 points from June to July 2025 after the CVS GLP-1 formulary change. In contrast, AOM semaglutide increased by +0.1 points...
What happens to cardiovascular health when patients stop taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications? That’s the focus of new research from investigators at Baylor Scott & White Research Institute and Stony Brook University Hospital,...
Biomarker testing has transformed cancer care over the past decade, opening the door to targeted therapies that can improve outcomes for patients with advanced disease. Yet despite strong guideline recommendations, many patients with metastatic non-small cell lung...
Multiple sclerosis (MS) affects approximately 1 million people in the United States, with women representing nearly 75% of patients. Over the past decade, consensus guidelines from leading MS experts have increasingly emphasized the importance of early intervention...
